BioPharma Resources

Therapeutic area

Gastroenterology and liver

MASH, cholestatic liver disease, GERD, IBS and short bowel syndrome. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

12

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

14

Industry-sponsored

Recruiting Phase 3

17

Industry-sponsored

Recruiting Phase 4 (post-approval)

2

Industry-sponsored

Recent approvals

All
  • Lyrfigtu (Lirafugratinib Hydrochloride) · Elevar NovelPriority reviewOrphanSep 23, 2026

    To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

  • Rasonque (Daraxonrasib) · Revolution Medicines NovelPriority reviewOrphanAug 26, 2026

    To treat metastatic pancreatic cancer

  • Bizengri (Zenocutuzumab-Zbco) · Merus N.V. Breakthrough therapyPriority reviewOrphanMay 8, 2026
  • Lynavoy (Linerixibat) · Intercept NovelOrphanMar 17, 2026

    To treat cholestatic pruritus associated with primary biliary cholangitis

  • Nereus (Tradipitant) · Vanda Pharms INC NovelDec 30, 2025

    To treat vomiting associated with motion

  • Bizengri (Zenocutuzumab-Zbco) · Merus N.V. NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDec 4, 2024

    To treat non-small cell lung cancer and pancreatic adenocarcinoma

  • Ziihera (Zanidatamab-Hrii) · Jazz Pharms NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanNov 20, 2024

    To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer

  • Vyloy (Zolbetuximab-Clzb) · Astellas NovelPriority reviewOrphanOct 18, 2024

    To treat gastric or gastroesophageal junction adenocarcinoma

  • Livdelzi (Seladelpar Lysine) · Gilead Sciences INC NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanAug 14, 2024

    To treat primary biliary cholangitis (PBC)

  • Iqirvo (Elafibranor) · Ipsen NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanJun 10, 2024

    To treat primary biliary cholangitis in combination with ursodeoxycholic acid

  • Rezdiffra (Resmetirom) · Madrigal NovelBreakthrough therapyAccelerated approvalPriority reviewMar 14, 2024

    To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring

  • Tevimbra (Tislelizumab-Jsgr) · Beigene NovelOrphanMar 13, 2024

    To treat unresectable or metastatic esophageal squamous cell carcinoma

Recruiting trials by phase

Industry-sponsored drug and biologic trials.

Most approvals since then, by company

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • AdebrelimabSHR-8068, HRS -4642Phase 341 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors

  • CadonilimabAK104Phase 331 trials

    Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

  • SHR-A1811Trastuzumab RezetecanPhase 327 trials

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • SerplulimabHLX10, HLX43Phase 325 trials

    Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • I-DXdDS-7300a, MK-2400Phase 317 trials

    Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

Largest recruiting Phase 3 trials

All

More: Gastroenterology and liver news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.